ISRG vs MDT: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

ISRG and MDT are similarly sized, but MDT trades noticeably cheaper on forward earnings (15.80x vs 32.51x): the market is paying up for ISRG's profile and pricing MDT more conservatively, or for faster growth. If you believe in growth, ISRG fits: analysts expect its revenue to rise 12% next year, against 4% for MDT. If you believe in paying less for profit, MDT fits: it trades at 15.8x forward earnings, against 32.51x for ISRG.

ISRG vs MDT: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricISRGMDTWhat it tells you
Market cap$140.52B$129.46BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E32.5115.80Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E49.0224.87Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta1.440.57Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range28% of range84% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book8.792.58How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: MDT is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how ISRG and MDT affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ISRG and MDT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ISRG and MDT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Intuitive Surgical (ISRG) do?

Intuitive Surgical (ISRG) is the dominant maker of robotic-assisted surgery systems, best known for the da Vinci platform used in minimally invasive procedures across urology, gynecology, general surgery, and other specialties. Its business model is razor-and-blade: Intuitive sells or places the large capital systems, then earns high-margin recurring revenue from the single-use instruments and accessories consumed in each procedure, plus service contracts. As the installed base of systems grows and procedure volumes rise, recurring revenue compounds. The company has expanded its platform with newer systems (including the da Vinci 5 and the Ion platform for lung biopsy), and benefits from surgeon training, hospital workflow integration, and a large library of validated procedures that create high switching costs. Intuitive went public in 2000 and is headquartered in Sunnyvale, California.

Full ISRG guide

What does Medtronic (MDT) do?

Medtronic is one of the largest medical device companies in the world, designing, manufacturing, and selling therapies and devices across a broad range of chronic and acute conditions. Its business spans three main areas after October 2026: Cardiovascular (pacemakers, defibrillators, heart valves, and cardiac ablation), Neuroscience (spine implants, neuromodulation for pain and movement disorders, and surgical navigation), and Medical Surgical (surgical stapling, energy devices, and a growing robotic-surgery platform). Its former Diabetes unit (insulin pumps and continuous glucose monitoring) was carved out as MiniMed, which listed on Nasdaq under MMED; on October 15, 2026 Medtronic exchanged its remaining 252.8 million MiniMed shares for Medtronic shares in an exchange offer that was 5.4 times subscribed, so it no longer owns any of MiniMed. The company sells primarily to hospitals, surgeons, and health systems, generating durable, recurring demand tied to procedure volumes and chronic-disease management. Medtronic's scale gives it deep relationships with providers, a large installed base of devices, and the resources to fund extensive R&D and acquisitions. Growth depends on new product cycles, pipeline approvals, and global expansion, especially in emerging markets. Founded in 1949 and headquartered in Ireland for tax purposes (operationally rooted in Minnesota), Medtronic is a large-cap, dividend-growing medical-technology company tied to long-term healthcare demand and aging demographics, with trailing revenue of about $37.5 billion as of November 2026. In November 2026 the FDA cleared the Hugo robotic-assisted surgery system for general surgery procedures in the US, extending it beyond urology into abdominal and soft-tissue operations, a pool of roughly 3.5 million upper and lower abdominal general-surgery procedures a year in the US. The shares are up about 11% over the three months to November 20, 2026, ahead of the November 24 report for the quarter ended October 2026, the first full quarter after the MiniMed exit.

Full MDT guide

ISRG vs MDT: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • ISRG drivers: Razor-and-blade recurring revenue; Installed base and switching costs.
  • MDT drivers: Diversified device portfolio; Innovation pipeline and new product cycles.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: ISRG trades at a premium valuation (about 49 times trailing earnings and 12 times sales as of November 2026), so any slowdown in procedure growth, system placements, or margins can compress the multiple sharply; the stock's 28% decline in 2026 despite double-digit growth shows how that can play out. For MDT, medtronic has at times delivered sluggish organic growth, raising concerns that its scale slows innovation relative to nimbler competitors like Boston Scientific and Edwards Lifesciences.

ISRG or MDT: which should you pick?

If the story you believe is ISRG's (Razor-and-blade recurring revenue), ISRG is the more direct way to own it; if it is MDT's (Diversified device portfolio), MDT is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ISRG and MDT guides.

ISRG vs MDT: the full fundamentals

ISRG. At about $405 on November 20, 2026, Intuitive trades near 49 times trailing GAAP earnings (depressed by the settlement charge) and 32 times forward earnings, cheaper than at the start of the year after a 28% share-price decline while adjusted earnings kept growing about 26%. The premium is still the central debate: bulls point to the durability of the razor-and-blade model, 14% procedure growth and five straight earnings beats, while bears point to multiple-compression risk if procedure growth slows or Medtronic and J&J gain share. The mean analyst target among 30 tracked by Yahoo was about $489 in November 2026.

MDT. At about $101 on November 20, 2026, Medtronic trades near 16 times forward earnings, a moderate multiple next to faster-growing medtech peers, while the GAAP trailing P/E of about 25x includes acquisition amortization. The 26 analysts tracked by Yahoo Finance hold a mean target near $107, and Leerink Partners raised its target to $117 from $111 in November. The next report, scheduled for November 24, 2026, will be the first read on the company after the MiniMed exit, with consensus at about $1.33 of EPS on $9.48 billion of revenue.

Headline figures (approximate, November 2026): ISRG shows revenue (ttm) ~$11.6B, q3 2026 revenue growth ~22% YoY (~$3.05B); da Vinci procedures up ~14%, gross / operating margin (ttm) ~67% / ~32%, net income (ttm) ~$3.0B (EPS ~$8.27); Q3 GAAP hit by $450M settlement charge; MDT shows revenue (ttm) ~$37.5 billion, up ~14% year over year in the July 2026 quarter, margins ~65% gross, ~20% operating, ~14% net, net income (ttm) ~$5.2 billion, eps ~$4.07 GAAP trailing; ~$6.41 forward estimate.

The bottom line: ISRG vs MDT

ISRG and MDT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ISRG and MDT exposure against your real portfolio. It is not an investment adviser.

Wondering how ISRG or MDT fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Intuitive Surgical

Ask Walnut's AI anything about ISRG and see how it fits what you own.

FAQ

What is the difference between ISRG and MDT?

+

Intuitive Surgical (ISRG) is the dominant maker of robotic-assisted surgery systems, best known for the da Vinci platform used in minimally invasive procedures across urology, gynecology, general surgery, and other specialties. Medtronic is one of the largest medical device companies in the world, designing, manufacturing, and selling therapies and devices across a broad range of chronic and acute conditions. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ISRG or MDT the better stock?

+

Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ISRG or MDT?

+

On forward P/E (as of November 2026), ISRG trades at 32.51x and MDT at 15.80x, so MDT is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ISRG and MDT?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ISRG vs MDT?

+

ISRG: ISRG trades at a premium valuation (about 49 times trailing earnings and 12 times sales as of November 2026), so any slowdown in procedure growth, system placements, or margins can compress the multiple sharply; the stock's 28% decline in 2026 despite double-digit growth shows how that can play out. Competition is intensifying as Medtronic (Hugo), Johnson & Johnson and others bring rival surgical-robotics platforms to market. Legal exposure became concrete in Q3 2026 with a $450 million pretax antitrust settlement charge that cut GAAP earnings. Hospital capital budgets are cyclical and can defer system purchases in tight economic periods. Reimbursement changes, regulatory scrutiny of new systems, and any safety or recall issues are risks. Tariffs cost the company about 0.9% of revenue in its 2026 margin guidance, and Q3 adjusted results included a one-time benefit from tariff refunds. The company is also exposed to global healthcare-spending trends and currency, and the high valuation leaves little room for execution missteps. MDT: Medtronic has at times delivered sluggish organic growth, raising concerns that its scale slows innovation relative to nimbler competitors like Boston Scientific and Edwards Lifesciences. The Hugo robotic platform faces an entrenched Intuitive Surgical, and Johnson & Johnson said in November 2026 it would install its first Ottava robot in a US hospital, so the broader Hugo clearance arrives into a more crowded field. The MiniMed separation removes diabetes but adds near-term noise: reported results, guidance and comparisons will shift as the unit leaves the numbers, and analysts expect EPS of about $1.33 on about $9.48 billion of revenue for the quarter ending October 2026, reported November 24, slightly below the year-earlier EPS of $1.36. Device companies face reimbursement pressure, hospital budget constraints, FDA approval and recall risk, and litigation exposure. A large international footprint brings currency headwinds, and debt stood near $28 billion against about $8.8 billion of cash as of the latest report. The stock is up only about 2% over the past year despite faster sales growth, though it gained about 11% in the three months to November 20, 2026. New-product execution, pipeline timing, and the ability to sustain organic growth remain the key swing factors for the investment case.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ISRG or MDT; figures are approximate and dated (as of November 2026). Verify current data before investing.